Outcomes | Anticipated absolute effects (95% CI) | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | Comments | |
---|---|---|---|---|---|---|
Risk with placebo | Risk with galcanezumab | |||||
Reduction of monthly migraine days follow up: 3 months | The mean reduction of monthly headache days was −2.7 days | The mean reduction of monthly headache days in the intervention group was 2.1 days lower (2.9 lower to 1.3 lower) | – | 836 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with Galcanezumab 120 mg reduces monthly migraine days slightly compared to placebo. |
Reduction of monthly acute treatment days follow up: 3 months | The mean reduction of monthly headache days was −2.2 days | The mean reduction of monthly acute treatment days in the intervention group was 2.5 days lower (3.3 lower to 1.8 lower)b | – | 836 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with Galcanezumab 120 mg reduces monthly acute treatment days slightly compared to placebo. |
Improvement in functional MIDAS score follow up: 3 months | The mean improvement in functional MIDAS score was −11.5 points | The mean improvement in functional MIDAS score in the intervention group was 8.7 points lower (16.4 lower to 1.1 lower) | – | 836 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with Galcanezumab 120 mg improves functional MIDAS score compared to placebo. |
At least 50% reduction of monthly migraine days follow up: 3 months | 149 per 1000 | 284 per 1000 (215 to 375) | RR 1.9112 (1.4477 to 2.5232) | 836 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with Galcanezumab 120 mg mg results in at least 50% reduction of monthly headache days compared to placebo. |
Serious adverse events follow up: 3 months | 7 per 1000 | 4 per 1000 (0 to 34) | RR 0.5288 (0.0594 to 4.7092) | 836 (1 RCT) | ⨁⨁⨁◯ MEDIUMa | Treatment with Galcanezumab 120 mg mg results in a possibly unimportant effect on serious adverse event occurrence compared to placebo. |
Mortality follow up: 3 months | 0 per 1000 | 0 per 1000 (0 to 0) | not estimable | 836 (1 RCT) | No deaths were observed with treatment with Galcanezumab 120 mg or placebo |